Hartford HealthCare has increased its stake in a California-based biotech company that’s developing regenerative antibodies to treat liver disease and inflammatory bowel disease.
The health system’s endowment fund first took a stake in Surrozen Inc. last March as part of a $50 million Series B investment round. Last week, Surrozen disclosed it had raised another $50 million, and that Hartford HealthCare and several other prior investors had pitched in more money.
Surrozen said the funds will help it seek approvals over the next two years from the U.S. Food and Drug Administration to advance its two drug candidates into human clinical trials.
The company says its antibodies engage the body’s own biological repair mechanisms, which could help repair various types of tissue and organs damaged by disease.
